Celgene and Agios win FDA approval for targeted AML drug Idhifa

Idhifa won the agency’s backing to treat relapsed/refractory AML patients with an IDH2 mutation, becoming the first such drug for a group that represents between 8% and 19% of all AML patients, according to a release from Celgene. It’s also the first oral, targeted inhibitor for the mutation to win agency backing.